Imfinzi plus transarterial chemoembolisation and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular…